Leaps by Bayer leads $80M Series A financing for Cellino Biotech to autonomize stem cell therapy manufacturing

Cellino Biotech, Inc., an autonomous cell therapy manufacturing company, today announced the completion of a Series A financing of $80 million, led by the impact investment arm of Bayer AG - Leaps by Bayer - 8VC, and Humboldt Fund. New investors in the round include Felicis Ventures and others, joining existing investors The Engine and Khosla Ventures. The company has raised a total of $96 million in gross proceeds from private financings to date.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news